Search Results for "eric"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for eric. Results 11 to 20 of 317 total matches.

Reducing Intake of Trans Fatty Acids

   
The Medical Letter on Drugs and Therapeutics • Aug 13, 2007  (Issue 1267)
EDITORIAL FELLOWS: Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School Eric J. Epstein ...
...
Med Lett Drugs Ther. 2007 Aug 13;49(1267):65-6 |  Show IntroductionHide Introduction

Tinidazole (Tindamax) - A New Option for Treatment of Bacterial Vaginosis

   
The Medical Letter on Drugs and Therapeutics • Sep 10, 2007  (Issue 1269)
., University of Michigan Medical School Eric J. Epstein, M.D., Albert Einstein College of Medicine SENIOR ...
Tinidazole (Tindamax - Mission Pharmacal), an oral antiprotozoal drug available in the US since 2004 for treatment of trichomoniasis, giardiasis, amebiasis and amebic liver abscess, was recently approved by the FDA for treatment of bacterial vaginosis.
Med Lett Drugs Ther. 2007 Sep 10;49(1269):73-4 |  Show IntroductionHide Introduction

Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2007  (Issue 1270)
: Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School Eric J. Epstein, M.D., Albert ...
Eculizumab (Soliris - Alexion) has been approved by the FDA for reduction of hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare form of hemolytic anemia. A recombinant humanized monoclonal antibody, eculizumab is the first drug to be marketed for this indication.
Med Lett Drugs Ther. 2007 Sep 24;49(1270):79-80 |  Show IntroductionHide Introduction

BRCA Screening

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2007  (Issue 1274)
: Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School Eric J. Epstein, M.D., Albert ...
Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast and ovarian cancer. Clinically important BRCA mutations have been found in about 2% of Ashkenazi Jewish women, and are estimated to occur in about 1 in 300 to 500 women in the general non-Jewish US population. The prevalence appears to be lower in non-whites.
Med Lett Drugs Ther. 2007 Nov 19;49(1274):93-4 |  Show IntroductionHide Introduction

Correction: Panitumumab Dosage

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
., University of Michigan Medical School Eric J. Epstein, M.D., Albert Einstein College of Medicine DRUG ...
In the CLINICAL STUDIES - Other Cancers paragraph (Med Lett Drugs Ther 2007; 49:35), the dosage in the first line should be 2.5 mg/kg, not 25 mg/kg.
Med Lett Drugs Ther. 2007 Jun 4;49(1262):48 |  Show IntroductionHide Introduction

Correction: The EarCheck Middle Ear Monitor

   
The Medical Letter on Drugs and Therapeutics • Aug 11, 2008  (Issue 1292)
INFORMATION: Susan Morey, Pharm.D. CONTRIBUTING EDITOR: Eric J. Epstein, M.D. Albert Einstein College ...
The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument's reading is determined not by the degree of protrusion of the tympanic membrane, but rather by its mobility.
Med Lett Drugs Ther. 2008 Aug 11;50(1292):64 |  Show IntroductionHide Introduction

Correction: CT Colonography

   
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008  (Issue 1301)
., M.P.H., University of Michigan Medical School Eric J. Epstein, M.D. Albert Einstein College of Medicine ...
(Med Lett Drugs Ther 2008; 50:94) In table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively.
Med Lett Drugs Ther. 2008 Dec 15;50(1301):97-100 |  Show IntroductionHide Introduction

Clarification: Half-Life of Heroin

   
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016  (Issue 1489)
. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein ...
A reader expressed concern that a statement in our article Naloxone (Narcan) Nasal Spray for Opioid Overdose (Med Lett Drugs Ther 2016; 58:1) might be misleading. We stated that heroin has a half-life of 2-6 minutes, which is correct, but heroin is a prodrug that is rapidly metabolized to 6-acetylmorphine and morphine. The risk of respiratory depression is related to those active metabolites, and it may persist well beyond the clearance of heroin from the blood.
Med Lett Drugs Ther. 2016 Feb 29;58(1489):32 |  Show IntroductionHide Introduction

In Brief: Plan B OTC

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006  (Issue 1243)
EDITORIAL FELLOWS: Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School Eric J. Epstein ...
The FDA has approved over-the-counter (OTC) sales of Plan B (Duramed), an emergency contraceptive package that contains two 0.75-mg tablets of levonorgestrel, to women ≥18 years old. Younger women still require a prescription. In one trial, two levonorgestrel 0.75-mg tablets taken 12 hours apart, the first within 72 hours after unprotected intercourse, decreased the pregnancy rate to 1%, compared to an expected rate of 8% (Task Force on Postovulatory Methods of Fertility Regulation, Lancet 1998; 352:428). How high doses of a progestin taken after coitus prevent pregnancy is unclear; they may...
Med Lett Drugs Ther. 2006 Sep 11;48(1243):75 |  Show IntroductionHide Introduction

In Brief: Influenza Developments

   
The Medical Letter on Drugs and Therapeutics • Mar 24, 2008  (Issue 1282)
INFORMATION: Susan Morey, Pharm.D. CONTRIBUTING EDITOR: Eric J. Epstein, M.D., Albert Einstein College ...
Recent reports (D Kaye.Clin Infect Dis April 1, 2008;46:iii) indicate that 2 of the 3 components of this year's influenza vaccine (Med Lett Drugs Ther 2007;49:81), the influenza B and A/H3N2 antigens, do not matchup well with circulating strains. The B component is probably not protective. The A/H3N2 antigen in the vaccine probably provides some protection, particularly for high-risk patients. The third component, the A/H1N1 antigen, is protective against circulating A/H1N1 influenza viruses, but these viruses, unlike previous A/H1N1 strains, are developing some resistance to oseltamivir...
Med Lett Drugs Ther. 2008 Mar 24;50(1282):21-4 |  Show IntroductionHide Introduction